CVM Latest Report

Key Financial Data

1. As of September 30, 2024, CEL-SCI Corporation's total operating revenue was -$61,204,040, an improvement from -$74,675,222 as of September 30, 2023, with a decrease of -$13,421,118, indicating a recovery trend in the Company's operating revenue.

2. Despite negative operating revenue, the Company's expenses on marketing, sales, and management decreased from $2,199,849 to $1,643,157, indicating effective cost control.

3. Research and development expenses decreased from $52,767,673 to $44,772,447, which may affect the Company's future revenue growth potential.

4. The industry competition and market environment put pressure on the Company's operating revenue, especially in the biopharmaceutical sector, where market demand and product promotion success directly affect earnings.

Peer Comparison

1. Industry-wide analysis: The biopharmaceutical industry as a whole faces increased competition and rising R&D costs, with many companies performing poorly in terms of revenue and profits. Some companies have seen revenue growth due to the launch of innovative drugs, but the overall trend is limited by the R&D cycle and market acceptance.

2. Peer evaluation analysis: Compared to peers, CEL-SCI's operating revenue performance is weaker, although it has improved, but it has not yet achieved profitability. Some competitors in the industry have achieved revenue growth through the successful launch of new products or market share expansion, so CEL-SCI needs to strengthen its marketing and product promotion strategies.

Summary

The financial data of CEL-SCI Corporation indicate that its operating revenue has improved but remains in a loss, showing challenges in market promotion and sales. Although cost control has been effective, the reduction in R&D expenses may affect the Company's future growth potential. The overall competitive environment and market demand changes in the biopharmaceutical industry have had a significant impact on the Company's operating status.

Opportunities

1. CEL-SCI is advancing the clinical study of D-1553, which may bring new revenue sources if successfully launched.

2. The Company plans to continue the R&D of multiple new drugs in 2024, expanding the pipeline of innovative drugs, providing potential for future revenue growth.

3. The industry policy support has increased, bringing more market opportunities for biopharmaceutical companies.

Risks

1. The operating revenue remains negative, indicating challenges in the Company's competition, which may affect investor confidence.

2. The reduction in R&D expenses may lead to a lack of future product innovation, limiting revenue growth potential.

3. Increased competition in the industry may lead to further compression of market share, increasing operating risks.